Oncology Central

New treatment strategy for patients with EGFR-mutant lung cancer


Activating EGFR mutations in non-small-cell lung cancer were discovered in 2004. Patients harboring these mutations, who have been treated with EGFR–tyrosine kinase inhibitor (TKI), are expected to live longer than 2 years. However, lung cancer eventually progresses and the patients die of the disease. Thus, alternative treatments are needed for EGFR-mutated lung cancer. Here, we review the alternative treatments for patients with activating EGFR mutation.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.